Researchers from the University of Arizona have unveiled that coordinated Y chromosome loss in both cancer cells and immune cells may explain the worse prognosis in people with this alteration. The loss of the Y chromosome (LOY) is one of the most frequent somatic mutations in men, particularly with advancing age. Investigating the mechanisms and effects of LOY in PBMCs and its association with immune and tumor cells, they “found a relationship between the Y chromosome loss in normal cells inside the tumor and the Y chromosome loss inside the cancer cell,” Dan Theodorescu, senior author of the study, told BioWorld. Read More

Current therapeutic options for Parkinson’s disease face significant challenges. Read More

Cancervax Inc. has successfully created a nanoparticle that can target specific cells that are potentially cancerous. Read More

Oncovita SAS’s lead oncolytic virus candidate, Mvdeltac, has been awarded orphan drug designation by the FDA. Read More

Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has disclosed compounds reported to be useful for the treatment of leukemia. Read More

Rakuten Medical Inc.’s RM-0256 has been selected for funding by Japan’s Agency for Medical Research and Development (AMED). Read More

Chronic pain is a constant challenge to around 20% of the global population, and treatments to mitigate such pain often cause unacceptable side effects because the receptors and signaling pathways involved in pain sensing also drive necessary processes in the heart, lungs and liver. Opioid analgesics can be effective against chronic pain, but they can lead to tolerance and addiction. Read More

Beijing Danatlas Pharmaceutical Technology Co. Ltd. has synthesized PPAR-γ modulators reported to be useful for the treatment of bladder cancer. Read More

Beijing Tide Pharmaceutical Co. Ltd. has identified protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer and myelofibrosis. Read More

Human adenovirus may cause severe infections in both immunosuppressed and immunocompetent individuals and there is no specific approved therapy for it to date. The incidence may be about 50%-60% in immunocompromised subjects, with mortality rates around 80% in patients with disseminated infections. Read More

Evotec International GmbH has divulged NLRP3 inflammasome inhibitors reported to be useful for the treatment of asthma, cryopyrin-associated periodic syndromes, hypertension, Alzheimer’s disease, rheumatoid arthritis, diabetes, multiple sclerosis and Parkinson’s disease. Read More

Kumquat Biosciences Inc. has described compounds acting as GTPase KRAS wild-type and mutant inhibitors reported to be useful for the treatment of cancer. Read More

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. and Nanjing Chia Tai Tianqing Pharmaceutical Co. Ltd. have announced IND clearance by China’s National Medical Products Administration (NMPA) for NTB-003 (formerly BCG-009) for thyroid eye disease. Read More